Anti-LILRA4, AlpHcAbs® Human antibody

Details and Advantages
Applications: ELISA,Flow Cyt
Reactivity: Human
Conjugate: Unconjugated
Advantages:

High lot-to-lot consistency

Increased sensitivity and higher affinity

Animal-free production

Summary >
Description:
Anti-LILRA4, AlpHcAbs® Human antibody is designed for detecting human LILRA4 specifically. Based on ELISA and/or FCM, Anti-LILRA4, AlpHcAbs® Human antibody reacts with human LILRA4 specifically.

Immunogen: Recombinant human LILRA4
Host: Alpaca pacous
Isotype: Human IgG1
Conjugate: Unconjugated
Specificity: Human LILRA4
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol
Storage: Store at –20 °C, (Avoid freeze / thaw cycles)

Background:
ILT7 is a pDC-specific IgG-like transcript and is a member of the leukocyte immunoglobulin-like receptor gene family. This receptor, in complex with FcER1a, transduces ITAM-mediated signals which negatively modulate type I IFN production by pDC. ILT7 is thus a potential target to regulate Type 1 IFN production by pDC, which play a major role during viral infection, auto-immune diseases and anti-cancer immunity. Additionally, ILT7, along with CD123 and BDCA-2, can be used to identify or classify subsets of pDCalong with TLR expression and TLR mediated immune responses.
Performance >
ELISA: 1:4,000-1:10000
Flow Cytometry:1:200-1:1000

Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.